Mylan Stock Buy Or Sell May 2026

The company expects 2026 to be a "pivotal year" with 2% revenue growth and $650 million in planned cost savings.

Viatris is currently viewed as a value play or income stock rather than a high-growth candidate. Its low valuation and steady dividends may make it a "buy" for long-term holders, while short-term traders might "hold" or "sell" due to flat price targets and operational headwinds. mylan stock buy or sell

Mylan (formerly NASDAQ: MYL) no longer exists as an independent stock. In November 2020, Mylan merged with Pfizer’s Upjohn business to form a new company called (NASDAQ: VTRS ). The company expects 2026 to be a "pivotal

To evaluate whether to "buy or sell," you must look at performance and analyst sentiment as of April 2026. Viatris (VTRS) Analyst Ratings & Price Targets (April 2026) Mylan (formerly NASDAQ: MYL) no longer exists as